Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosfomycin plus Ceftazidime for Severe Gram-negative Infections
NCT07063095Phase 3Recruiting
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fosfomycin in Gram-negative bacterial infection. Started Aug 2025; status: recruiting.
02
Drugs
fosfomycin
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT07063095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07063095.